New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first evidence ...
GRAND CAYMAN, Cayman Islands, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback